Literature DB >> 19454608

Assessment of damage in vasculitis: expert ratings of damage.

Philip Seo1, David Jayne, Raashid Luqmani, Peter A Merkel.   

Abstract

OBJECTIVES: Current measures of damage in vasculitis do not account for the possibility that some forms of damage may exert greater impact than others. As part of an international effort to revise how damage is quantified in vasculitis clinical research, an exercise was performed to measure expert ratings of damage items.
METHODS: Members of the Vasculitis Clinical Research Consortium and European Vasculitis Study Group were given a list of 129 items of damage related to WG and microscopic polyangiitis (MPA). Participants were asked to rate each item of damage on an integer scale from 0 to 10, where 10 represented the most severe form of damage and 0 indicated 'no impact'.
RESULTS: A multidisciplinary panel of 50 investigators from North America, Europe and Australia-New Zealand participated. The highest median ratings (8-10) were assigned to items of damage associated with malignancy, tissue ischaemia, the central nervous system and cardiopulmonary manifestations. The mean scores ranged from 1.3 to 9.5. The highest s.d.s (>or=2.5) were associated with forms of damage that may benefit from surgical intervention or may not be causally associated with WG or MPA. Lower scores were assigned by nephrologists in comparison with rheumatologists and by Americans in comparison to Europeans, although the difference in median ranks used by these groups was not statistically significant (P > 0.05 for the comparisons).
CONCLUSIONS: This exercise represents an important step in the development of a weighting system that may increase the utility of damage index scores for the assessment of patients with vasculitis.

Entities:  

Mesh:

Year:  2009        PMID: 19454608      PMCID: PMC2722812          DOI: 10.1093/rheumatology/kep103

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

Review 1.  Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

Authors:  Peter A Merkel; Philip Seo; Peter Aries; Tuhina Neogi; Alexandra Villa-Forte; Maarten Boers; David Cuthbertson; David T Felson; Bernhard Hellmich; Gary S Hoffman; David R Jayne; Cees G M Kallenberg; Jeffrey Krischer; Alfred Mahr; Eric L Matteson; Ulrich Specks; Raashid Luqmani; John Stone
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

Review 2.  Wegener's granulomatosis: managing more than inflammation.

Authors:  Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2008-01       Impact factor: 5.006

3.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

Review 4.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  O Flossmann; P Bacon; K de Groot; D Jayne; N Rasmussen; P Seo; K Westman; R Luqmani
Journal:  Postgrad Med J       Date:  2008-03       Impact factor: 2.401

5.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Authors:  Philip Seo; Yuan-I Min; Janet T Holbrook; Gary S Hoffman; Peter A Merkel; Robert Spiera; John C Davis; Steven R Ytterberg; E William St Clair; W Joseph McCune; Ulrich Specks; Nancy B Allen; Raashid A Luqmani; John H Stone
Journal:  Arthritis Rheum       Date:  2005-07

6.  The future of damage assessment in vasculitis.

Authors:  Philip Seo; Raashid A Luqmani; Oliver Flossmann; Bernhard Hellmich; Karen Herlyn; Gary S Hoffman; David Jayne; Cees G M Kallenberg; Carol A Langford; Alfred Mahr; Eric L Matteson; Chetan B Mukhtyar; Tuhina Neogi; Abraham Rutgers; Ulrich Specks; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

  6 in total
  14 in total

1.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

2.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

3.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 4.  Advances in the diagnosis, assessment and outcome of Takayasu's arteritis.

Authors:  Fatma Alibaz-Oner; Sibel Zehra Aydin; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

Review 5.  Assessment of disease activity and progression in Takayasu's arteritis.

Authors:  Haner Direskeneli; Sibel Z Aydin; Peter A Merkel
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

6.  Evaluation of damage in giant cell arteritis.

Authors:  Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

Review 7.  Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Authors:  Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

8.  Current status of outcome measure development in vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Christina Cornell; Haner Direskeneli; Don Gebhart; Gulen Hatemi; Raashid Luqmani; Eric L Matteson; Nataliya Milman; Joanna Robson; Philip Seo; Gunnar Tomasson
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

9.  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Authors:  Peter A Merkel; Karen Herlyn; Alfred D Mahr; Tuhina Neogi; Philip Seo; Michael Walsh; Maarten Boers; Raashid Luqmani
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

Review 10.  Patient-Reported Outcomes in Glomerular Disease.

Authors:  David T Selewski; Aliza Thompson; Sarrit Kovacs; Elektra J Papadopoulos; Noelle E Carlozzi; Howard Trachtman; Jonathan P Troost; Peter A Merkel; Debbie S Gipson
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.